A Study Evaluating IV Oncaspar® and IV Gemzar® in the Treatment of Solid Tumors and Lymphoma

This study has been terminated.

( No recommended Phase II dose was determined. )

Study NCT00363610 Information provided by Enzon Pharmaceuticals, Inc.

First Received: August 9, 2006 Last Updated: May 16, 2008 History of Changes

No Study Results Posted for this Study

Study Status:	This study has been terminated.
Estimated Study Completion Date:	June 2008
Primary Completion Date:	November 2007 (Final data collection date for primary outcome measure)